Yang David D, Muralidhar Vinayak, Mahal Brandon A, Beard Clair J, Mouw Kent W, Martin Neil E, Orio Peter F, King Martin T, Nguyen Paul L
Harvard Medical School.
Harvard Radiation Oncology Program.
Am J Clin Oncol. 2018 Oct;41(10):953-959. doi: 10.1097/COC.0000000000000410.
Following radical prostatectomy (RP), adjuvant radiation therapy (RT) decreases biochemical recurrence and potentially improves metastasis-free and overall survival for patients with high-risk pathologic features. Since adjuvant RT typically occurs daily over several weeks, the logistical challenges of extensive traveling may be a significant barrier to its use. We examined the association between distance to treatment facility and use of adjuvant RT.
We identified 97,568 patients in the National Cancer Database diagnosed from 2004 through 2011 with cT1-4N0-xM0-x prostate cancer and found to have high-risk pathologic features (pT3-4 stage and/or positive surgical margins) at RP. Multivariable logistic regression adjusting for sociodemographic and clinicopathologic factors was used to examine the association between travel distance and receipt of adjuvant RT, defined as radiotherapy initiated within 12 months after RP.
Overall, 10.6% (10,346) of the study cohort received adjuvant RT. On multivariable analysis, increasing travel distance was significantly associated with decreased use of adjuvant RT, with adjusted odds ratios of 1.0 (reference), 0.67, 0.46, 0.39, and 0.32 (all P<0.001) and prevalence of use at 12.6%, 8.8%, 6.3%, 4.9%, and 3.7% for patients living ≤25.0, 25.1 to 50.0, 50.1 to 75.0, 75.1 to 100.0, and >100.0 miles away, respectively.
Increasing travel distance was strongly associated with decreased use of adjuvant RT in this national cohort of postprostatectomy patients with high-risk pathologic features. These results strongly suggest that the logistical challenges of extensive travel are a significant barrier to the use of adjuvant RT. Efforts aimed at improving access to radiotherapy and reducing treatment time are urgently needed.
根治性前列腺切除术后(RP),辅助放疗(RT)可降低生化复发率,并可能提高具有高危病理特征患者的无转移生存率和总生存率。由于辅助放疗通常需要在数周内每日进行,频繁出行带来的后勤保障问题可能是限制其应用的一个重要障碍。我们研究了到治疗机构的距离与辅助放疗使用之间的关联。
我们在国家癌症数据库中识别出97568例于2004年至2011年期间被诊断为cT1 - 4N0 - xM0 - x前列腺癌且在RP时具有高危病理特征(pT3 - 4期和/或手术切缘阳性)的患者。采用多变量逻辑回归分析,对社会人口统计学和临床病理因素进行校正,以研究出行距离与辅助放疗使用情况之间的关联,辅助放疗定义为在RP后12个月内开始的放疗。
总体而言,研究队列中有10.6%(10346例)接受了辅助放疗。在多变量分析中,出行距离增加与辅助放疗使用减少显著相关,校正后的比值比分别为1.0(参照)、0.67、0.46、0.39和0.32(均P<0.001),居住距离≤25.0英里、25.1至50.0英里、50.1至75.0英里、75.1至100.0英里和>100.0英里的患者的使用患病率分别为12.6%、8.8%、6.3%、4.9%和3.7%。
在这个全国性的具有高危病理特征的前列腺切除术后患者队列中,出行距离增加与辅助放疗使用减少密切相关。这些结果强烈表明,频繁出行带来的后勤保障问题是辅助放疗应用的一个重要障碍。迫切需要努力改善放疗的可及性并缩短治疗时间。